Insight Capital Research & Management Inc. purchased a new position in Cigna Corporation (NYSE:CI) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,204 shares of the health services provider’s stock, valued at approximately $1,908,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of CI. IFP Advisors Inc grew its holdings in Cigna by 5.3% during the 2nd quarter. IFP Advisors Inc now owns 2,296 shares of the health services provider’s stock worth $384,000 after acquiring an additional 116 shares in the last quarter. First Trust Advisors LP grew its holdings in Cigna by 1.1% during the 2nd quarter. First Trust Advisors LP now owns 117,015 shares of the health services provider’s stock worth $19,587,000 after acquiring an additional 1,261 shares in the last quarter. Trillium Asset Management LLC grew its holdings in Cigna by 2.7% during the 2nd quarter. Trillium Asset Management LLC now owns 160,414 shares of the health services provider’s stock worth $26,852,000 after acquiring an additional 4,272 shares in the last quarter. Savant Capital LLC boosted its holdings in shares of Cigna by 45.9% in the 2nd quarter. Savant Capital LLC now owns 2,290 shares of the health services provider’s stock valued at $383,000 after buying an additional 720 shares in the last quarter. Finally, Dupont Capital Management Corp boosted its holdings in shares of Cigna by 36.6% in the 2nd quarter. Dupont Capital Management Corp now owns 71,635 shares of the health services provider’s stock valued at $11,991,000 after buying an additional 19,212 shares in the last quarter. Hedge funds and other institutional investors own 87.85% of the company’s stock.
In related news, CAO Mary T. Hoeltzel sold 575 shares of Cigna stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $197.03, for a total value of $113,292.25. Following the sale, the chief accounting officer now owns 2,499 shares of the company’s stock, valued at approximately $492,377.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Alan Muney sold 15,345 shares of Cigna stock in a transaction on Monday, November 27th. The shares were sold at an average price of $200.80, for a total transaction of $3,081,276.00. Following the completion of the sale, the executive vice president now directly owns 28,457 shares in the company, valued at approximately $5,714,165.60. The disclosure for this sale can be found here. Insiders have sold a total of 35,956 shares of company stock worth $7,165,490 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.
Shares of Cigna Corporation (NYSE:CI) opened at $209.16 on Tuesday. The company has a market cap of $51,768.04, a P/E ratio of 20.23, a PEG ratio of 1.60 and a beta of 0.50. Cigna Corporation has a one year low of $131.03 and a one year high of $212.46. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.39 and a current ratio of 0.39.
Cigna (NYSE:CI) last issued its quarterly earnings data on Thursday, November 2nd. The health services provider reported $2.83 EPS for the quarter, topping analysts’ consensus estimates of $2.36 by $0.47. The business had revenue of $10.38 billion for the quarter, compared to analysts’ expectations of $10.17 billion. Cigna had a net margin of 5.74% and a return on equity of 18.85%. The business’s revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company earned $1.94 EPS. research analysts forecast that Cigna Corporation will post 10.34 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on the stock. BidaskClub upgraded shares of Cigna from a “buy” rating to a “strong-buy” rating in a report on Friday, August 18th. Morgan Stanley raised their price target on shares of Cigna from $188.00 to $195.00 and gave the company an “overweight” rating in a report on Thursday, August 17th. BMO Capital Markets began coverage on shares of Cigna in a research report on Monday, October 16th. They issued a “market perform” rating and a $210.00 price objective for the company. Citigroup increased their price objective on shares of Cigna from $198.00 to $231.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Finally, Jefferies Group increased their price objective on shares of Cigna from $201.00 to $221.00 and gave the company a “buy” rating in a research report on Friday, October 13th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Cigna currently has an average rating of “Buy” and a consensus target price of $201.50.
COPYRIGHT VIOLATION WARNING: This story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thelincolnianonline.com/2017/12/12/insight-capital-research-management-inc-takes-1-91-million-position-in-cigna-corporation-ci.html.
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Want to see what other hedge funds are holding CI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cigna Corporation (NYSE:CI).
Receive News & Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related companies with MarketBeat.com's FREE daily email newsletter.